239 related articles for article (PubMed ID: 21481981)
1. [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis].
Sastre-Garriga J; Montalban X
Neurologia; 2011 Nov; 26(9):556-62. PubMed ID: 21481981
[TBL] [Abstract][Full Text] [Related]
2. [Biological treatment of multiple sclerosis].
Sørensen PS; Sellebjerg F
Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of multiple sclerosis.
Di Pauli F; Berger T; Reindl M
Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
[TBL] [Abstract][Full Text] [Related]
4. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab (Millennium/ILEX).
Dumont FJ
Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
[TBL] [Abstract][Full Text] [Related]
6. Emerging monoclonal antibody therapies for multiple sclerosis.
Cree B
Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal antibodies for the treatment of multiple sclerosis].
Sánchez-Seco VG; Casanova Peño I; Arroyo González R
Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis - established and novel therapeutic approaches.
Ehling R; Berger T; Reindl M
Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):3-15. PubMed ID: 20236038
[TBL] [Abstract][Full Text] [Related]
9. Treating multiple sclerosis with monoclonal antibodies.
Buttmann M; Rieckmann P
Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
[TBL] [Abstract][Full Text] [Related]
10. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C; Haggiag S; Ruggieri S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
[TBL] [Abstract][Full Text] [Related]
11. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
Trebst C; Voss E; Skripuletz T; Stangel M
Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
[TBL] [Abstract][Full Text] [Related]
12. Current and future disease-modifying therapies in multiple sclerosis.
Lim SY; Constantinescu CS
Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
[TBL] [Abstract][Full Text] [Related]
13. [Development of new therapies for multiple sclerosis].
Holmøy T; Celius EG
Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
15. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
16. [Ocular side effects of drugs used in the treatment of multiple sclerosis].
Santos-Bueso E; Serrador-García M; García-Sánchez J
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):493-5. PubMed ID: 24257261
[No Abstract] [Full Text] [Related]
17. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
18. [Alemtuzumab and multiple sclerosis].
Nau JY
Rev Med Suisse; 2008 Nov; 4(178):2425. PubMed ID: 19051633
[No Abstract] [Full Text] [Related]
19. Treatment options for multiple sclerosis: current and emerging therapies.
Gawronski KM; Rainka MM; Patel MJ; Gengo FM
Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
